Scilex Holding Company to Present Oral, Poster Presentations and Symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek Conference in Las Vegas, NV on September 3-5, 2024
Scilex Holding Company (Nasdaq: SCLX), a non-opioid pain management company, will present research on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek conference in Las Vegas, NV, September 3-5, 2024. Key highlights include:
1. A non-CME presentation by Dr. Charles Argoff on September 4, discussing pain relief options when gabapentinoids are insufficient.
2. Two presentations by Dr. Srinivas Nalamachu on September 5, comparing Lidocaine Topical System 1.8% to Lidocaine 5% Patch, focusing on decreased opioid utilization and cost effectiveness.
These presentations aim to showcase ZTlido's potential in addressing unmet needs in pain management, particularly for patients with neuropathic pain conditions like PHN.
Scilex Holding Company (Nasdaq: SCLX), una compagnia di gestione del dolore non oppioide, presenterà ricerche su ZTlido (sistema topico di lidocaina) al conferenza annuale PAINWeek 2024 a Las Vegas, NV, dal 3 al 5 settembre 2024. I punti salienti includono:
1. Una presentazione non CME da parte del Dr. Charles Argoff il 4 settembre, che discuterà le opzioni per il sollievo dal dolore quando i gabapentinoidi sono insufficienti.
2. Due presentazioni del Dr. Srinivas Nalamachu il 5 settembre, che confronteranno Sistema Topico di Lidocaina 1.8% con il cerotto di lidocaina al 5%, concentrandosi sulla riduzione dell'utilizzo di oppioidi e sull'efficacia dei costi.
Queste presentazioni mirano a mettere in evidenza il potenziale di ZTlido nell'affrontare le esigenze non soddisfatte nella gestione del dolore, in particolare per i pazienti con condizioni di dolore neuropatico come il PHN.
Scilex Holding Company (Nasdaq: SCLX), una compañía de manejo del dolor no opioide, presentará investigaciones sobre ZTlido (sistema tópico de lidocaína) en la conferencia anual PAINWeek 2024 en Las Vegas, NV, del 3 al 5 de septiembre de 2024. Los puntos destacados incluyen:
1. Una presentación no CME del Dr. Charles Argoff el 4 de septiembre, hablando sobre opciones para el alivio del dolor cuando los gabapentinoides son insuficientes.
2. Dos presentaciones del Dr. Srinivas Nalamachu el 5 de septiembre, comparando Sistema Tópico de Lidocaína 1.8% con el parche de lidocaína al 5%, enfocándose en la disminución de la utilización de opioides y la efectividad de costos.
Estas presentaciones tienen como objetivo mostrar el potencial de ZTlido para abordar las necesidades no satisfechas en el manejo del dolor, particularmente para pacientes con condiciones de dolor neuropático como el PHN.
Scilex Holding Company (Nasdaq: SCLX)는 비오피오이드 통증 관리 회사로서, 2024년 9월 3일부터 5일까지 네바다주 라스베이거스에서 열리는 2024 연례 PAINWeek 컨퍼런스에서 ZTlido (리도카인 국소 시스템)에 대한 연구를 발표합니다. 주요 하이라이트는 다음과 같습니다:
1. 9월 4일 Dr. Charles Argoff에 의한 비CME 발표로, 가바펜틴 제제가 충분하지 않은 경우의 통증 완화 옵션에 대해 논의합니다.
2. 9월 5일 Dr. Srinivas Nalamachu가 두 번 발표하며 리도카인 국소 시스템 1.8%와 리도카인 5% 패치를 비교하고, 오피오이드 사용 감소와 비용 효율성에 중점을 둡니다.
이 프레젠테이션은 ZTlido의 잠재력을 부각시켜 필요가 충족되지 않은 통증 관리 분야, 특히 PHN과 같은 신경병리 통증 조건을 가진 환자들에게 도움이 되는 것을 목표로 합니다.
Scilex Holding Company (Nasdaq: SCLX), une société de gestion de la douleur non opioïde, présentera des recherches sur ZTlido (système topique de lidocaïne) lors de la conférence annuelle PAINWeek 2024 à Las Vegas, NV, du 3 au 5 septembre 2024. Les points clés incluent :
1. Une présentation non CME par Dr. Charles Argoff le 4 septembre, discutant des options de soulagement de la douleur lorsque les gabapentinoïdes sont insuffisants.
2. Deux présentations par Dr. Srinivas Nalamachu le 5 septembre, comparant Système Topique de Lidocaïne 1.8% au patch de lidocaïne à 5%, en mettant l'accent sur la diminution de l'utilisation des opioïdes et l'efficacité des coûts.
Ces présentations visent à mettre en avant le potentiel de ZTlido pour répondre aux besoins non satisfaits en matière de gestion de la douleur, en particulier chez les patients atteints de douleurs neuropathiques telles que le PHN.
Scilex Holding Company (Nasdaq: SCLX), ein Unternehmen für nicht-opioide Schmerztherapie, wird auf der 2024 Annual PAINWeek Conference in Las Vegas, NV, vom 3. bis 5. September 2024, Forschungsarbeiten zu ZTlido (lokales Lidocainsystem) vorstellen. Zu den wichtigsten Highlights gehören:
1. Eine nicht-CME-Präsentation von Dr. Charles Argoff am 4. September, die Optionen zur Schmerzlinderung erörtert, wenn Gabapentinoide nicht ausreichen.
2. Zwei Präsentationen von Dr. Srinivas Nalamachu am 5. September, die Lidocain Topisches System 1.8% mit dem Lidocain 5% Pflaster vergleichen, wobei der Schwerpunkt auf der Senkung des Opioidverbrauchs und der Kosten-Effektivität liegt.
Diese Präsentationen zielen darauf ab, das Potenzial von ZTlido bei der Bewältigung unerfüllter Bedürfnisse im Schmerzmanagement, insbesondere bei Patienten mit neuropathischen Schmerzsyndromen wie PHN, zu zeigen.
- None.
- None.
PALO ALTO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced oral, poster presentations, and symposia on ZTlido (lidocaine topical system) at the 2024 Annual PAINWeek conference in Las Vegas, NV on September 3-5, 2024.
Key highlights of the ZTlido (lidocaine topical system)
- September 4, 2024 (Wednesday)
- NON-CME Presentation in the Castellana Ballroom.
- 12:00PM PT - 1:00PM PT
- TITLE: What to do when pain relief with Gabapentinoids isn’t enough?
- SPEAKER: Dr. Charles Argoff
- DESCRIPTION: Gabapentinoids (gabapentin and pregabalin) are the foundational analgesics used to treat neuropathic pain of PHN, and their usage has grown rapidly in recent years given increasing scrutiny around opioid prescribing. The unmet need, though, remains high, given the challenges with titrating them to an effective dose. Dr Charles Argoff will review what analgesic options exist to optimize gabapentinoids, and the trade-offs that come with different agents. Dr. Argoff is Professor of Neurology and Director of the Comprehensive Pain Program at Albany Medical Center in New York. He is an internationally renowned for his work in Pain Management - in research, teaching and patient care, and serves as the President of AAPM (American Academy of Pain Management).
- September 5, 2024 (Thursday)
- 5:50PM PT – 6:00PM PT: Decreased Opioid Utilization with Lidocaine Topical System
1.8% Compared to Lidocaine5% Patch: A Retrospective Claims Analysis to be Presented by Srinivas Nalamachu, M.D. - 6:05PM PT – 6:15PM PT: Decreased Cost Utilization with Lidocaine Topical System
1.8% Compared to Lidocaine5% Patch: A Retrospective Claims Analysis to be Presented by Srinivas Nalamachu, M.D.
- 5:50PM PT – 6:00PM PT: Decreased Opioid Utilization with Lidocaine Topical System
For more information on Scilex Holding Company, refer to www.scilexholding.com.
For more information on Scilex Holding Company Sustainability Report, refer to www.scilexholding.com/investors/sustainability.
For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system)
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system)
Scilex Holding Company is headquartered in Palo Alto, California.
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding estimates for the gout treatment market and affected patient population, estimates for potential demand for Gloperba, the belief that Scilex is well-positioned to market and distribute Gloperba, Scilex’s expectations for Gloperba to be the first liquid colchicine formulation allowing providers to prescribe precision dosing and Scilex’s expectations for Gloperba to last more than 30 days in patients who are treated with lower doses than 0.6 mg.
Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the unpredictability of trading markets; general economic, political and business conditions; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is the subject of an exclusive, transferable license to Scilex Holding Company to use the registered trademark.
ELYXYB® is a registered trademark owned by Scilex Holding Company.
All other trademarks are the property of their respective owners.
© 2024 Scilex Holding Company All Rights Reserved.
FAQ
When and where is Scilex Holding Company (SCLX) presenting research on ZTlido at PAINWeek 2024?
What topics will Dr. Charles Argoff discuss in his presentation on ZTlido at PAINWeek 2024?
What will Dr. Srinivas Nalamachu present about ZTlido at PAINWeek 2024?
How does Scilex Holding Company (SCLX) aim to address pain management with ZTlido?
